Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer

Memorial Sloan Kettering Cancer Center383 enrolled

Overview

The purpose of this project is to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles (BRACA1 185delAG and 5382insC; BRCA2 6174delT) among Jewish women.

Study Type

OBSERVATIONAL

Enrollment

383

Conditions

Breast Cancer

Interventions

Blood testOTHER

subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.

QuestionnaireOTHER

A questionnaire encompassing medical, environmental exposure, and reproductive history.

Eligibility

Sex: FEMALEMin age: 19 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients are eligible for the study if they are over 18 years of age, identify their ancestry as Jewish (both Sephardic and Ashkenazi Jews are eligible), have or have had a diagnosis of breast cancer, and are able to give informed consent. * Relatives, age 18 or older, of the patients who meet eligibility criteria above and are found to have a specific BRCA1 or BRCA2 mutation if they are able to give informed consent.

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Outcomes

Primary Outcomes

to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles among Jewish women.

Time frame: through study completion, an average of 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.